RxDoctor Payments Data

Christine Lucas, MD

Family Medicine · Anna, ILNPI 1346248374

Payments from drug & device makers

$796in general payments, 2019–2025

Across 62 payments — averaging $12.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$441
  • Alkermes, Inc.$122
  • Astellas Pharma US Inc$100
  • Amgen$40
  • Johnson & Johnson$27
  • Pfizer$23
  • plus $42 from 3 others

What the payments were for

  • Food & beverage$69687%
  • Education$10013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)51$441
Alkermes, Inc.2$122
Astellas Pharma US Inc1$100
Amgen3$40
Johnson & Johnson1$27
Pfizer1$23
GSK1$16
Sobi, Inc1$14
Novo Nordisk1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$796 in reported general payments places this provider in the 70th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$6,425
Medicare patients
188
Services billed
429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide37$39,218
EliquisApixaban26$31,995
JardianceEmpagliflozin12$19,014
JanuviaSitagliptin Phosphate17$18,251
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$17,082
TrulicityDulaglutide12$11,214
Aimovig AutoinjectorErenumab-Aooe12$8,973
Synjardy XrEmpagliflozin/Metformin Hcl13$7,778
Novolog FlexpenInsulin Aspart11$4,995
Albuterol Sulfate HfaAlbuterol Sulfate106$2,869
ShingrixVaricella-Zoster Ge/As01b/Pf13$2,801
Pregabalin13$2,773
Gabapentin155$2,189
PradaxaDabigatran Etexilate Mesylate11$2,166
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen76$1,865

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$31,99526 claims
GSKShingrix$16$2,80113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Anna

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →